Salud financiera de hoja de balance de Vascular Biogenics

Salud financiera controles de criterios 6/6

Vascular Biogenics tiene un patrimonio de los accionistas total de $19.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $24.6M y $5.4M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$24.26m
Patrimonio	US$19.24m
Total pasivo	US$5.41m
Activos totales	US$24.65m

Actualizaciones recientes sobre salud financiera

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

May 18

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Dec 24

Recent updates

VBL Therapeutics receives non-compliance letter from Nasdaq

Sep 01

VBL Therapeutics GAAP EPS of -$0.12

Aug 15

VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals

Jul 19

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

May 18

Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump

Sep 03

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

Mar 17

How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

Jan 28

VBL Therapeutics expands the ovarian cancer trial in Europe

Dec 29

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Dec 24

Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 19

VBL Therapeutics EPS beats by $0.01, misses on revenue

Nov 16

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($24.5M) de VBLT superan a sus pasivos a corto plazo ($5.3M).

Pasivo a largo plazo: Los activos a corto plazo de VBLT ($24.5M) superan a sus pasivos a largo plazo ($108.0K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: VBLT está libre de deudas.

Reducción de la deuda: VBLT no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: VBLT tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: VBLT dispone de suficiente cash runway para 1.2 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 15.7% cada año.

Salud financiera de hoja de balance de Vascular Biogenics

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Vascular Biogenics Ltd. Receives Non-Compliance Notice from Nasdaq

VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Recent updates

Vascular Biogenics Ltd.(NasdaqCM:VBLT) dropped from NASDAQ Composite Index

Notable Labs, Inc. completed the acquisition of Vascular Biogenics Ltd. (NasdaqGM:VBLT) from Aurum Ventures MKI Ltd. and others in reverse merger transaction.

Vascular Biogenics Ltd. Approves Board Appointments

Vascular Biogenics Ltd. Receives Non-Compliance Notice from Nasdaq

Full year 2022 earnings released: US$0.42 loss per share (vs US$0.45 loss in FY 2021)

An unknown buyer entered into an agreement to acquire Manufacturing facility in Modiin, Israel and certain related assets from Vascular Biogenics Ltd. (NasdaqGM:VBLT) for $7.1 million.

VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

VBL Therapeutics receives non-compliance letter from Nasdaq

VBL Therapeutics GAAP EPS of -$0.12

VBL Therapeutics Announces Workforce Reduction

Price target increased to US$6.00

Vbl Therapeutics Announces Top-Line Data from Phase 3 Oval Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer

VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals

Vascular Biogenics Ltd., Annual General Meeting, Jul 07, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

Vascular Biogenics Ltd. to Report Q1, 2022 Results on May 17, 2022

Consensus forecasts updated

No longer forecast to breakeven

VBL Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation for Ofra-Vec (Ofranergene Obadenovec or VB-111) in Combination with Paclitaxel for Treatment of Platinum-Resistant Ovarian Cancer

Consensus forecasts updated

VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as Planned

Forecast to breakeven in 2024

Vascular Biogenics Ltd. announced that it expects to receive €15 million in funding from European Innovation Council

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.12 loss in 3Q 2020)

VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the Oval Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer

Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 2Q 2020)

High number of new directors

VBL Therapeutics Provides Update on Oval, A Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

VBL Therapeutics Announces Addition of Progression Free Survival as A Second Primary Endpoint in OVAL, A Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

Vbl Therapeutics to Provide an Update on the Oval Phase 3 Registration Enabling Study of Vb-111 in Ovarian Cancer At the 2021

Price target increased to US$5.20

Consensus forecasts updated

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.15 loss in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: US$0.56 loss per share (vs US$0.54 loss in FY 2019)

Vascular Biogenics Ltd. to Report Q4, 2020 Results on Mar 25, 2021

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme

VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients

How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

New 90-day high: US$2.50

Price target raised to US$4.50

VBL Therapeutics Announces First Patient in Europe in the OVAL Trial

VBL Therapeutics expands the ovarian cancer trial in Europe

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

New 90-day high: US$1.96

Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

Third quarter 2020 earnings released: US$0.12 loss per share

Revenue and earnings miss expectations

VBL Therapeutics EPS beats by $0.01, misses on revenue

New 90-day low: US$1.07

Vascular Biogenics Ltd. to Report Q3, 2020 Results on Nov 16, 2020

Vascular Biogenics Ltd. Announces Resignation of Susan Kelley as an Independent Director

Vascular Biogenics Ltd. Announces Board Changes

New 90-day low - US$1.16

First half earnings released

Vascular Biogenics Ltd. to Report Q2, 2020 Results on Aug 13, 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera